JP2022540197A - エーリキアワクチンおよび免疫原性組成物 - Google Patents

エーリキアワクチンおよび免疫原性組成物 Download PDF

Info

Publication number
JP2022540197A
JP2022540197A JP2022501147A JP2022501147A JP2022540197A JP 2022540197 A JP2022540197 A JP 2022540197A JP 2022501147 A JP2022501147 A JP 2022501147A JP 2022501147 A JP2022501147 A JP 2022501147A JP 2022540197 A JP2022540197 A JP 2022540197A
Authority
JP
Japan
Prior art keywords
immunogenic composition
seq
trp36
trp140
bacterin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022501147A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540197A5 (enExample
Inventor
ジェレ ダブリュ． マクブライド
ポール ジェイ． ドミノウスキ
スマン マハン
ジェイソン ジェイ． ミラーシップ
ダンカン エム． ムワンギ
シャラス ライ
シャロン エム． ワッペル
Original Assignee
リサーチ ディベロップメント ファウンデーション
ゾエティス サービシズ リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リサーチ ディベロップメント ファウンデーション, ゾエティス サービシズ リミテッド ライアビリティ カンパニー filed Critical リサーチ ディベロップメント ファウンデーション
Publication of JP2022540197A publication Critical patent/JP2022540197A/ja
Publication of JP2022540197A5 publication Critical patent/JP2022540197A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1246—Rickettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2022501147A 2019-07-12 2020-07-13 エーリキアワクチンおよび免疫原性組成物 Pending JP2022540197A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962873843P 2019-07-12 2019-07-12
US62/873,843 2019-07-12
US201962879762P 2019-07-29 2019-07-29
US62/879,762 2019-07-29
US202063049476P 2020-07-08 2020-07-08
US63/049,476 2020-07-08
PCT/US2020/041779 WO2021011456A1 (en) 2019-07-12 2020-07-13 Ehrlichia vaccines and immunogenic compositions

Publications (2)

Publication Number Publication Date
JP2022540197A true JP2022540197A (ja) 2022-09-14
JP2022540197A5 JP2022540197A5 (enExample) 2023-07-20

Family

ID=71948757

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022501147A Pending JP2022540197A (ja) 2019-07-12 2020-07-13 エーリキアワクチンおよび免疫原性組成物

Country Status (11)

Country Link
US (1) US12624093B2 (enExample)
EP (1) EP3996741A1 (enExample)
JP (1) JP2022540197A (enExample)
CN (1) CN114514238A (enExample)
AU (1) AU2020314625A1 (enExample)
BR (1) BR112022000347A2 (enExample)
CA (1) CA3146842A1 (enExample)
CL (1) CL2022000086A1 (enExample)
MX (1) MX2022000525A (enExample)
PH (1) PH12022550081A1 (enExample)
WO (1) WO2021011456A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025118050A1 (pt) * 2023-12-04 2025-06-12 Laboratório Bio-Vet Ltda Antígeno vacinal quimérico com ação tríplice contra erliquiose, anaplasmose e babesiose canina, vetor de expressão, célula recombinante, composição vacinal, kit de diagnóstico, método de tratamento e uso de proteína quimérica

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006505270A (ja) * 2002-11-04 2006-02-16 リサーチ ディベロップメント ファウンデーション イヌおよびヒトエールリヒア症の免疫診断のためのｐ１５３およびｐ１５６抗原ならびにその使用
WO2006138509A2 (en) * 2005-06-16 2006-12-28 Research Development Foundation Immunoreactive protein orthologs of ehrlichia canis and e. chaffeensis
JP2008500962A (ja) * 2004-03-11 2008-01-17 ワイス エールリヒア症に対する保護のためのイヌワクチン
JP2011525911A (ja) * 2008-06-27 2011-09-29 ファイザー・インク 新規なアジュバント組成物
EP2433646A1 (en) * 2010-09-22 2012-03-28 Intervet International BV Vaccine against Ehrlichia canis and associated methods
JP2013532140A (ja) * 2010-05-28 2013-08-15 ゾエティス・ベルジャム・エス・アー 抗原および免疫調節ワクチンおよびコレステロール、ならびにその使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043085A (en) * 1998-08-27 2000-03-28 Research Development Foundation Ehrlichia canis 120-kDa immunodominant antigenic protein and gene
CA2555413C (en) 2004-02-25 2013-12-17 Research Development Foundation An immunoreactive 38-kda ferric binding protein of ehrlichia canis and uses thereof
US7910593B2 (en) 2004-04-09 2011-03-22 Chugai Seiyaku Kabushiki Kaisha Water-soluble prodrugs
US7842474B2 (en) * 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
EP3527582B1 (en) * 2005-04-04 2022-08-17 IDEXX Laboratories, Inc. Ehrlichia canis diva (differentiate infected from vaccinated animals)
EP1790656A1 (en) 2005-11-25 2007-05-30 Nanokem S.A. Solution-phase synthesis of leuprolide
WO2008000070A1 (en) * 2006-06-27 2008-01-03 Wellington Laboratories Inc. Glycyrrhetinic acid derivatives
EP2064231B2 (en) 2006-08-31 2020-08-26 Research Development Foundation Immunoreactive glycoprotein gp19 of ehrlichia canis
CL2008001806A1 (es) 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
WO2009102509A2 (en) 2008-01-10 2009-08-20 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
CA2796563C (en) 2009-04-28 2018-05-22 Research Development Foundation Immunoreactive ehrlichia p120/p140 epitopes and uses thereof
CA2874966C (en) * 2012-05-31 2020-06-09 Zoetis Services Llc Vaccination with canine respiratory coronavirus for protection against b. bronchiseptica infections
SI3542819T1 (sl) 2013-05-14 2021-11-30 Zoetis Services Llc Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide
KR20200039025A (ko) 2013-09-19 2020-04-14 조에티스 서비시즈 엘엘씨 유성 아쥬반트
MX2020011887A (es) 2018-05-07 2021-03-29 Res Found Dev Polipéptidos inmunorreactivos.
AU2019311181A1 (en) 2018-07-27 2021-02-18 Research Development Foundation Chimeric immunogenic polypeptides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006505270A (ja) * 2002-11-04 2006-02-16 リサーチ ディベロップメント ファウンデーション イヌおよびヒトエールリヒア症の免疫診断のためのｐ１５３およびｐ１５６抗原ならびにその使用
JP2008500962A (ja) * 2004-03-11 2008-01-17 ワイス エールリヒア症に対する保護のためのイヌワクチン
WO2006138509A2 (en) * 2005-06-16 2006-12-28 Research Development Foundation Immunoreactive protein orthologs of ehrlichia canis and e. chaffeensis
JP2011525911A (ja) * 2008-06-27 2011-09-29 ファイザー・インク 新規なアジュバント組成物
JP2013532140A (ja) * 2010-05-28 2013-08-15 ゾエティス・ベルジャム・エス・アー 抗原および免疫調節ワクチンおよびコレステロール、ならびにその使用
EP2433646A1 (en) * 2010-09-22 2012-03-28 Intervet International BV Vaccine against Ehrlichia canis and associated methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C KUYLER DOYLE; ET AL, INFECTION AND IMMUNITY, vol. VOL:74, NR:1, JPN5022010938, 2006, US, pages 711 - 720, ISSN: 0005561508 *
JEEBA A KURIAKOSE; ET AL, MICROBES AND INFECTION, vol. VOL:14, NR:12, JPN5022010937, October 2012 (2012-10-01), FR, pages 1054 - 1063, ISSN: 0005561509 *

Also Published As

Publication number Publication date
BR112022000347A2 (pt) 2022-04-12
CL2022000086A1 (es) 2022-09-30
CN114514238A (zh) 2022-05-17
AU2020314625A1 (en) 2022-02-03
EP3996741A1 (en) 2022-05-18
WO2021011456A1 (en) 2021-01-21
MX2022000525A (es) 2022-04-20
CA3146842A1 (en) 2021-01-21
PH12022550081A1 (en) 2023-04-12
US20220356231A1 (en) 2022-11-10
US12624093B2 (en) 2026-05-12

Similar Documents

Publication Publication Date Title
KR100517028B1 (ko) 경피 면역용 조성물
Nordly et al. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators
US7001890B1 (en) Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination
CN101001646B (zh) 稳定化的合成免疫原投递系统
Riese et al. Vaccine adjuvants: key tools for innovative vaccine design
CN103260642B (zh) 分枝杆菌抗原组合物
ES2678694T3 (es) Vacuna
TWI589298B (zh) 陽離子之脂質疫苗組合物及其使用方法
EA002167B1 (ru) Вакцинная композиция против малярии
JP6505084B2 (ja) 免疫刺激性オリゴヌクレオチドを含む新規のワクチン組成物
JP2026082987A (ja) クロストリディオイデス（クロストリジウム）・ディフィシル（ｃｌｏｓｔｒｉｄｉｏｉｄｅｓ（ｃｌｏｓｔｒｉｄｉｕｍ）ｄｉｆｆｉｃｉｌｅ）に対する免疫応答を誘発するための免疫原性組成物および方法
US12624093B2 (en) Ehrlichia vaccines and immunogenic compositions
AU2016297529A1 (en) Liposomal adjuvant compositions
RU2824881C2 (ru) Вакцины против ehrlichia и иммуногенные композиции
KR20070117551A (ko) 점막 백신의 전달용 펩티드
TW201138815A (en) Peptide vaccine
CN118765203A (zh) 一种新型阳离子佐剂组合物
JP2001151698A (ja) インフルエンザワクチン
US20090087456A1 (en) Adjuvanted vaccine
US11766473B2 (en) Therapeutic cancer vaccine containing tumor-associated neoantigens and immunostimulants in a deliver system
JP2022540197A5 (enExample)
Gheibihayat et al. Mechanisms and performances of adjuvants in vaccine immunogenicity
Ebensen et al. Infection Prevention: Oil-and Lipid-Containing Products in Vaccinology
WO2023240278A2 (en) Uses of glycolipids as a vaccine adjuvant and methods thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230711

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250930